Theory and Practice of Compounding Ointments

Total Page:16

File Type:pdf, Size:1020Kb

Theory and Practice of Compounding Ointments COMPOUNDING FOR SCALP DISORDERS AND CONDITIONS Y. Pramar, Ph.D., Professor of Pharmaceutics Xavier University of Louisiana, College of Pharmacy, New Orleans, Louisiana. Goals: The goals of this article are to provide information on the physiology and disorders of the scalp, and typical drug therapy used to treat these disorders. Objectives: At the conclusion of this lesson, the reader should be able to: 1. Discuss the physiology of the scalp and the function of the sebum, sweat glands and pores. 2. List at least five disorders/conditions of the scalp. 3. Describe different treatment approaches used in scalp disorders. 4. Become familiar with various formulations used in the treatment of seborrheic dermatitis, dandruff, psoriasis, hair loss, lice and ringworm. Introduction Scalp disorders may be painful, annoying, unsightly and Pores: The pores in the skin are where the hair follicles embarrassing. Scalp problems may require short-term reside. The pore size is related to sebaceous gland size. treatment, but many of them need long-term therapy Pores enlarge to accommodate a greater oil flow. Acne over months, and sometimes years. Compounding caused by blocked pores often clears up when the pores pharmacists have a significant role in achieving enlarge allowing unimpeded movement of sebum successful therapeutic outcomes in this emerging field. through the pore. Anatomy and Physiology Sweat Glands: Sweat glands consist of a single tube, the The scalp consists primarily of the skin, sweat glands, lower portion of which is coiled into a ball and the upper sebaceous glands, hair shafts, and hair. When these part (the duct) opens onto the surface of the skin. There appendages are not functioning properly in harmony are two types of sweat glands, the eccrine and the with one another, various scalp disorders can occur. apocrine. The eccrine sweat glands, distributed all over the body, primarily regulate body temperature and Scalp: The scalp is the portion of the body consisting of eliminate toxic substances and waste products; the skin and subcutaneous tissue normally containing hair perspiration is clear and consists of traces of salt, that covers the neuro-cranium. It is especially rich in carbohydrates, protein and oil. The sweat they produce blood vessels; therefore, profuse bleeding may occur is primarily odorless. The apocrine sweat glands are with scalp injuries. The functions of the scalp (skin) primarily in the underarm area, around the nipples and in include protection and excretion. It secretes metabolic the genital area. They are stimulated by the same waste materials and toxins in order to rid the body of hormones that stimulate hair growth in the underarms them. It also secretes sweat to cool the body, and sebum and genital area. The fluid they secrete is milky and rich to protect the skin. in organic material that is subject to bacterial decay, causing body odor. The hair entraps both sweat and Skin: Each layer of the skin (epidermis, dermis, bacteria. subcutaneous) has a specific function. Included in the skin are the sebaceous glands that produce sebum and Sebum: When the sebum gets stuck in the pores, secrete it through the sebaceous ducts into hair follicles, whiteheads, blackheads, papules, pimples and cysts can where it migrates to the surface of the skin. This flow of ultimately occur. It is a result of the sebum getting sebum removes dead skin cells that flake off from inside blocked during its transport and clumping with dead skin the hair follicle. Sebum consists of fatty acids and other cells, being acted upon by bacteria and ultimately substances and protects the skin by reducing the blocking the opening to the skin surface. If pressure evaporation of water from the skin and blocks the builds up, pustules and cysts result. penetration of excess water into the skin. This sebum is one of two constituents making up the lipid film present Hair: Hair grows on the scalp and each hair filament on the skin surface, the other being the lipids of the originates in a deep hair follicle which penetrates into epidermal cells. the dermis. At the base of the follicle is the papilla which is the center of hair growth containing the capillaries and nerves that supply the hair. As new cells Treatment: The treatment selected for psoriasis of the are formed and older cells are pushed upward, they scalp is based on its extent and severity. Therapy can be gradually die and harden into a hair shaft, consisting of initiated using a corticosteroid preparation. Other two layers, the cuticle and cortex. The outer layer, the measures include tar preparations, such as coal tar cuticle, consists of flat, colorless, overlapping cells. The solution (LCD, Liquor Carbonis Detergens), anthralin, cortex contains pigment and a tough protein called calcipotriene and tazarotene. Treatment can be initiated keratin, forming the bulk of the hair shaft. Coarse hair, with a tar shampoo used daily. For thick scales on the as on the scalp, contains an additional inner core called scalp, a 6% salicylic acid gel, or a phenol : mineral oil : the medulla. The hair is lubricated by sebaceous glands glycerin mixture can be used. Alternatively, that are located in the hair follicle. In general, human fluocinolone acetonide 0.01% in oil can be applied under scalp hair is shed every two to four years; body hairs are a shower cap at night followed by tar shampoo in the shed more frequently. morning. Corticosteroids such as triamcinolone, fluocinolone, betamethasone dipropionate, fluocinonide, Hair growth: Hair growth is cyclical, consisting of three amcinonide, or clobetasol in solution form can be used phases. The growing phase is the “Anagen” phase; twice daily. about 90% of scalp hairs are in the anagen phase at any point in time. On a daily basis, about 50 to 100 scalp Hair Loss follicles go into the resting phase, or the “Catagen” I. Description: Pattern, or androgenetic baldness, is the phase, which involves 1% of the hairs daily. The most common form of alopecia. It is of genetic shedding phase is the “Telogen” phase and predetermination with the earliest changes occurring on approximately 10-20% of scalp hairs may be in the the front sides of the scalp and at the crown of the skull. telogen phase at any point in time. The extent of hair loss is variable and unpredictable, but may be experienced by approximately 80% of all men. SCALP DISORDERS AND THEIR TREATMENT Treatment: A 5% solution of minoxidil alone or in combination with other active ingredients can be used in Seborrheic Dermatitis and Dandruff both male and female patients, generally twice daily. Description: Seborrheic dermatitis is an acute or chronic Those that respond are usually less than five years into papulosquamous dermatitis presenting with dry scales their hair loss. and underlying erythema. In some cases pruritis is present. Dandruff occurs when there is a mild scaling II. Description: Alopecia areata is believed to be the without any erythema, and can occur if the scalp is dry result of an imuunologic process. Typically, there are or oily. It may be the result of several factors, including patches that are smooth, without scarring. Tiny hairs, hormonal imbalance, impaired metabolic nutrition, diet, generally 2-3 mm in length, may be seen. In some cases, tension, increased bacterial and fungal activity, all the scalp hair may eventually be involved. Alopecia biochemical changes in the scalp, the use of topical areata is a self-limiting disease where there may be medications and cosmetics. Seborrheic dermatitis complete re-growth of hair in about 80% of cases. In occurs when there is general erythema without tight, some cases, mild alopecia areata is resistant to therapy. thick, silvery scales. Psoriasis is evidenced by the presence of well-demarcated red plaques. Treatment: Severe forms may be treated by systemic corticosteroids; however, recurrences generally occur Treatment: Routine treatment for seborrhea of the scalp when therapy is discontinued. Corticosteroids can also involves a shampoo that may contain tar, zinc pyrithione be administered intralesionally; for example or selenium, used daily if necessary. A ketoconazole 1% triamcinolone acetonide 2.5 to 10 mg/mL can be injected or 2% shampoo can be used twice weekly. If needed, in aliquots of 0.1 mL every 1 to 2 cm in the involved solutions or lotions of topical corticosteroids can be used areas. The total dose should not exceed 30 mg per twice daily. month for adults. Another treatment includes daily use of anthralin 0.5% ointment. Psoriasis Description: Psoriasis is an inflammatory skin disease Other therapeutic approaches involve the use of topical that may be based upon a genetic predisposition. When diphenylcyclopropenone and squaric acid dibutyl ester. the skin is injured or irritated, it tends to induce lesions These agents serve to sensitize the skin; this is followed of psoriasis at the site. There are several variants of by application of progressively weaker concentrations psoriasis, with the most common being the plaque type. designed to produce a slight dermatitis. This results in Psoriasis presents as silvery scales on bright red, well- hair re-growth in 3 to 6 months in some patients. demarcated plaques that may be accompanied by itching. 2 III. Description: Drug-induced alopecia may result from Rx Hydrocortisone 1% Antipruritic Scalp Lotion thallium, excessive vitamin A, retinoids, antimitotic Hydrocortisone 1 g agents, anticoagulants, antithyroid drugs, oral Menthol 250 mg contraceptives, trimethadione, allopurinol, propranolol, Polysorbate 80 0.25 mL indomethacin, amphetamines, salicylates, gentamicin Ethanol 95% 25 mL and levodopa. Drug-induced alopecia is very Propylene glycol 25 mL disconcerting to the patient, but it is reversible when the Purified water, qs 100 mL causative agent is discontinued. Mix the hydrocortisone and menthol with the Treatment: No real treatment is indicated in such cases, Polysorbate 80.
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Drugs That Are Not Covered
    Drugs that are Not Covered* Current 10/1/21 In addition to this list, newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee has had an opportunity to review the medication, to determine whether the medication will be covered and if so, which tier will apply based on safety, efficacy and the availability of other products within that class of medications. The current list of newly marketed drugs can be found on our New to Market Drug list. Abilify tablets albuterol HFA inhalers (authorized Apexicon E cream Abilify MyCite tablets generics for ProAir, Proventil, Ventolin Apidra vials Absorica capsules HFA inhalers) Apidra SoloStar injection Absorica LD capsules Aldactone tablets Aplenzin tablets Abstral sublingual tablets Aldara cream Apriso capsules Acanya gel and pump gel Alkindi sprinkle capsules Arava tablets Accupril tablets Allegra Children’s Allergy ODT Arazlo lotion acetaminophen 320.5 mg/caffeine 30 Allegra ODT, suspension and tablets Arestin microspheres mg/dihydrocodeine 16 mg Alltizal tablets Aricept tablets capsulesAciphex tablets alogliptin (authorized generic for Aricept ODT Aciphex Sprinkle capsules Nesina) Arimidex tablets Acticlate tablets alogliptin/metformin tablets (authorized Arixtra injection Active-Prep kits generic for Kazano) ArmonAir Digihaler inhaler Activella tablets alogliptin/pioglitazone (authorized ArmonAir Respiclick inhaler Actonel tablets generic for Oseni) Aromasin tablets Actoplus Met tablets Alphagan P 0.1% eye drops Arthrotec 50 and 75 tablets Actos
    [Show full text]
  • A List of Medications That May Lower Your Patients' Costs
    A list of medications that may lower your patients’ costs INTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically sound and that it supports patient health. This committee reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. FORMULARY DESIGN There are numerous formulary designs that can be used by a pharmacy benefits administrator. Catamaran has chosen a formulary structure which is open and incentive based. Open Formulary: features co‐payments for medications that are preferred and non‐ preferred brands, plus lower co‐payments for generic drugs. Incentive Based: features different co‐payments for medications that are on or off the formulary. In this type of formulary, the patient cost structure may be two‐tier, three‐ tier, or four‐tier design. USING THIS FORMULARY REFERENCE GUIDE TO HELP CONTAIN COSTS Many benefit sponsors use the Catamaran formulary to help manage the overall cost of providing prescription drug benefits. This formulary offers a wide range of medications from which to choose. We realize that this formulary reference guide may not include every drug from every manufacturer. However, choosing a preferred drug when it is appropriate can provide access to the necessary medications to stay healthy, at a cost that is more affordable. KNOWING HOW THE FORMULARY INFORMATION IS ORGANIZED The following formulary reference guide is designed so that generic products are listed first in each drug category. The preferred brand name products are listed next, and non‐preferred brand products are listed last.
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Topical Salicylic Acid and Lactic Acid Microemulsion
    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Research Article Organic & Medicinal Chem IJ Volume 2 Issue 3 - May 2017 DOI: 10.19080/OMCIJ.2017.02.555587 Copyright © All rights are reserved by Maher Aljamal Topical Salicylic acid and Lactic acid Microemulsion Maher Aljamal1,2*, Ibrahim Kayali2 and Mohammad Abul-Haj2 1BeitJala Pharmaceutical Company / Research and Development department, Palestine 2Department of Chemistry, Palestine, Al- Quds university, Israel Submission: April 26, 2017; Published: May 02, 2017 *Corresponding author: Maher Aljamal, BeitJala Pharmaceutical Company / Research and Development department, Al- Quds university, Palestine, Tel: ; Email: Abstract Microemulsionsare used to solubilizing and improve an active pharmaceutical ingredientssolubility and permeability, such as those for topical absorption availability. The objective of this study was to prepare a microemulsion liquid composed of 12% salicylic acid and 4% of lactic acid using castor oil, Tween 80, propylene glycol, ethyl alcohol and purified water. Using the low energy emulsification technique; four andpseudo transparent/translucent ternary phase diagrams microemulsion. were constructed The Resultsand studied indicate for ata leastclear, 75thermodynamic days under a titrationmicroemulsion method liquid using obtainedpurified waterin each (with of the or without propylene glycol), each phase diagram was investigated at 25°C, 37°C and 45°C. The phases include conventional emulsion, viscous using low concentration of Tween 80. It was suggested that microemulsions of 12% Salicylic acid and 4% Lactic acid could be a suitable vehicleconstructed for topical phase treatment diagrams ofat psoriasis, all temperatures scaly patches, of study. ichthyoses, Using propylene dandruff, glycol corns, as calluses, a co-surfactant, and wartson lead the to handsmore orstable feet.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Antifungal and Antibiotic Powders
    ANTIFUNGAL AND ANTIBIOTIC POWDERS Antifungals: Econazole Powder, Ketoconazole Powder, Nyamyc (nystatin) Powder, Nystop (nystatin) Powder Antibiotics: Mupirocin Powder, Tobramycin Powder, Vancomycin Powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy powder products have the potential for misuse. Misuse of these powder products is quite common and it is important to inform patients about the possible complications due to overuse of these drugs. Regulatory Status FDA approved indication: Antifungal agents kill fungi or inhibit their growth. Antifungals that kill fungi are called fungicidal while those that inhibit their growth are called fungistatic. Antibiotics, or antimicrobials, are medications that destroy or slow down the growth of bacteria.
    [Show full text]
  • Product Monograph Cyclocort
    PRODUCT MONOGRAPH PrCYCLOCORT® amcinonide USP Cream, USP 0.1% w/w Ointment, USP 0.1% w/w Lotion 0.1% w/w Topical Corticosteroid GlaxoSmithKline Inc. Date of Revision: 7333 Mississauga Road November 4, 2014 Mississauga, Ontario L5N 6L4 www.stiefel.ca Submission Control No: 175944 ©2014 GlaxoSmithKline Inc., All Rights Reserved ®CYCLOCORT is a registered trade-mark owned by GlaxoSmithKline Inc. November 4, 2014 Page 1 of 17 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION.................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................. 4 ADVERSE REACTIONS ............................................................................................... 8 DRUG INTERACTIONS ............................................................................................... 8 DOSAGE AND ADMINISTRATION ........................................................................... 9 OVERDOSAGE ........................................................................................................... 11 STORAGE AND STABILITY ..................................................................................... 11 SPECIAL HANDLING INSTRUCTIONS
    [Show full text]